Anthem Biosciences IPO Allotment Status 2025: Check Date, Link & Next Steps

In the dynamic landscape of the Indian stock market, Initial Public Offerings (IPOs) frequently capture the attention of investors seeking new avenues for growth. The recent Anthem Biosciences IPO has been no exception, drawing significant interest from a diverse range of applicants. As the bidding period concludes, the focus now shifts to the crucial phase of allotment – a moment of anticipation for many. This comprehensive guide aims to demystify the process of checking your Anthem Biosciences IPO allotment status for 2025, providing clear, actionable steps and essential dates. Beyond the procedural aspects, we will also delve into a pertinent question for many Muslim investors: Is investment in IPOs, particularly one like Anthem Biosciences, permissible (Halal) in Islam? Our objective is to offer a resource that is not only factually precise and timely but also deeply aligned with ethical and Islamic financial principles, ensuring that your investment journey is both informed and conscientious.

How to Check Anthem Biosciences IPO Allotment Status

Once the Anthem Biosciences IPO allotment is finalized, investors can ascertain their status through several official channels. It is crucial to rely on these verified sources to ensure accuracy and avoid misinformation. Below are the detailed steps for checking your allotment status:

1. On BSE Website:

The Bombay Stock Exchange (BSE) provides a dedicated portal for checking IPO allotment statuses. Follow these steps:

• Step 1: Navigate to the official BSE IPO allotment status page: https://www.bseindia.com/investors/appli_check.aspx
• Step 2: Under ‘Issue Type’, select ‘Equity’.
• Step 3: From the ‘Issue Name’ dropdown menu, choose ‘Anthem Biosciences Limited’.
• Step 4: You will then have the option to enter either your ‘Application Number’ or your ‘PAN’ (Permanent Account Number).
• Step 5: Complete the ‘I am not a robot’ verification and click on the ‘Search’ button.

Your Anthem Biosciences IPO allotment status will be displayed on the screen.

2. On Registrar’s Website (kfintech IPO):

kfintech has been appointed as the official registrar for the Anthem Biosciences IPO. Registrars are responsible for the allotment process and maintaining records of shareholders. Here’s how to check on their platform:

• Step 1: Visit the kfintech IPO allotment status page: https://kosmic.kfintech.com/ipostatus/
• Step 2: In the ‘Select IPO’ dropdown menu, choose ‘Anthem Biosciences Limited’.
• Step 3: You can then select one of three options to check your status: ‘Application No’, ‘Demat Account’, or ‘PAN’.
• Step 4: Enter the required details corresponding to your chosen option.
• Step 5: Input the Captcha code for verification and click ‘Submit’.

The allotment status for your application will be shown.

3. On NSE Website:

The National Stock Exchange (NSE) also offers a facility to check IPO allotment status. The steps are as follows:

• Step 1: Go to the NSE allotment status page: https://www.nseindia.com/invest/check-trades-bids-verify-ipo-bids
• Step 2: Select ‘Equity and SME IPO bids’.
• Step 3: Choose ‘Anthem Biosciences Limited’ from the ‘Issue Name’ dropdown menu.
• Step 4: Enter your ‘PAN’ and ‘Application Number’.
• Step 5: Click on ‘Submit’.

Your Anthem Biosciences IPO allotment status will be displayed.

It is advisable to check your status on at least two of these platforms to cross-verify the information and ensure accuracy. Remember, the allotment process is typically finalized on the date specified in the IPO timeline, and the status will be available shortly thereafter.

Anthem Biosciences IPO Timeline

Understanding the key dates associated with the Anthem Biosciences IPO is crucial for investors to track their application and plan for subsequent actions. The timeline for this public offering is as follows:

Event	Date
IPO Opened	July 14, 2025
IPO Closed	July 16, 2025
Allotment Finalization	July 17, 2025
Refunds Begin	July 18, 2025
Shares Credited to Demat	July 18, 2025
Listing Date on NSE/BSE	July 21, 2025

IPO Details (Quick Summary)

For a concise overview of the Anthem Biosciences IPO, refer to the key details summarized below:

Details	Information
IPO Size	₹3,395.00 crore (entirely Offer-for-Sale of 5.96 crore equity shares)
Price Band	₹570 per share
Lot Size	To be confirmed, typically available in the IPO prospectus
Listing Exchanges	BSE, NSE
Category Demand
Overall	63.86 times
Retail	5.64 times
NII	42.36 times
QIBs	182.65 times

Is IPO Investment Halal in Islam?

For Muslim investors, the permissibility of investing in an Initial Public Offering (IPO) is a critical consideration. Islamic finance principles dictate that investments must adhere to Shariah law, which prohibits interest (riba), involvement in forbidden industries (haram), and excessive uncertainty (gharar). Therefore, an IPO investment is considered Halal if the company’s core business activities are Shariah-compliant (e.g., not involved in alcohol, gambling, or conventional banking) and its financial structure meets specific quantitative criteria (e.g., low debt, minimal non-compliant revenue). While Anthem Biosciences operates in the pharmaceutical sector, a thorough review of its business model and financial ratios against established Shariah screening standards is essential. Consulting with a qualified Islamic finance scholar or Shariah advisory board is always recommended for personalized guidance on specific IPOs, ensuring alignment with ethical and religious obligations.

Understanding Grey Market Premium (GMP) and its Implications

The Grey Market Premium (GMP) is an unofficial indicator that reflects the market’s expectation of an IPO’s listing price. It is the premium at which IPO shares are traded in the grey market before their official listing on the stock exchanges. While not a definitive predictor, GMP can offer insights into investor sentiment and potential listing gains.

For the Anthem Biosciences IPO, the Grey Market Premium has been observed at ₹144 per share. This suggests that investors are willing to pay an additional ₹144 above the issue price of ₹570, leading to an estimated listing price of ₹714 per share. This represents a potential premium of approximately 25.26% over the IPO price.

Key Considerations Regarding GMP:

• Unofficial Indicator: It is crucial to remember that GMP is an unofficial, unregulated indicator. It is influenced by demand and supply in the grey market, which can be volatile and speculative.
• Investor Sentiment: A high GMP often indicates strong investor interest and positive sentiment towards the company and its IPO. Conversely, a low or negative GMP might suggest a lack of enthusiasm.
• Not a Guarantee: GMP is not a guarantee of listing performance. The actual listing price can be influenced by various factors, including overall market conditions, company-specific news, and investor behavior on the listing day.
• Shariah Perspective: From an Islamic finance perspective, engaging in grey market trading (which often involves forward contracts and speculation without actual possession of the underlying asset) can raise concerns regarding gharar (excessive uncertainty) and maysir (gambling). While the GMP itself is an indicator, direct participation in grey market trading for speculative gains might not align with Shariah principles that emphasize tangible assets and risk-sharing.

Investors should use GMP as merely one piece of information among many, and not as the sole basis for their investment decisions. A comprehensive analysis of the company’s fundamentals, industry outlook, and the IPO’s valuation remains paramount.

What to Do After Allotment: Next Steps for Investors

Once the Anthem Biosciences IPO allotment status is declared, investors will fall into one of two categories: those who have received an allotment and those who have not. Understanding the next steps for each scenario is crucial for efficient portfolio management.

For Allotted Investors:

Congratulations if you have received an allotment! Your journey with Anthem Biosciences shares is just beginning. Here’s what typically happens next:

1. Shares Credited to Demat Account: On July 18, 2025, the allotted shares will be credited directly to your Demat account. You can verify this by checking your Demat account statement or contacting your depository participant (DP).
2. Listing on Exchanges: Anthem Biosciences shares are scheduled to be listed on both the BSE and NSE on July 21, 2025. On this day, the shares will begin trading on the secondary market. You can buy or sell shares through your brokerage account.
3. Monitor Performance: After listing, it is advisable to closely monitor the share price performance. Factors such as market sentiment, company news, and overall economic conditions will influence the stock’s movement.
4. Long-Term vs. Short-Term Strategy: Revisit your investment strategy. Did you invest for short-term listing gains or for long-term growth? Your initial objective should guide your decision to hold or sell the shares. For long-term investors, a deeper analysis of the company’s fundamentals and future prospects is warranted.

For Non-Allotted Investors:

If you did not receive an allotment, do not be disheartened. IPOs are often oversubscribed, and allotment is a lottery-based process for retail investors. Here’s what you can expect:

1. Refunds Initiated: Refunds for unsuccessful applications will begin on July 18, 2025. The application money will be unblocked or credited back to your bank account. Ensure that your bank account details provided during the application process were accurate.
2. Re-evaluate Opportunities: The market is dynamic, and new investment opportunities frequently arise. You can re-evaluate other upcoming IPOs or consider investing in the secondary market. If you are still interested in Anthem Biosciences, you can consider purchasing shares from the open market after listing, keeping in mind the prevailing market price.
3. Learn from the Experience: Analyze why the IPO was oversubscribed and what factors led to the high demand. This can provide valuable insights for future IPO applications.

Important Note on Refunds: If you do not receive your refund within a few business days after the refund initiation date, contact your bank or the IPO registrar (kfintech) for assistance. Ensure you have your application number and other relevant details ready.

Factors Influencing IPO Allotment

IPO allotment is not merely a matter of application; it is a complex process influenced by several factors, especially in oversubscribed issues like Anthem Biosciences. Understanding these factors can help investors manage their expectations and strategize for future IPO applications.

1. Subscription Levels:

The most significant factor influencing allotment is the overall subscription level. When an IPO is heavily oversubscribed, the chances of allotment for individual investors decrease significantly. For Anthem Biosciences, the overall subscription of 63.86 times indicates very high demand, making allotment challenging.

• Retail Portion: The retail portion, subscribed 5.64 times, is allotted on a proportionate basis, meaning if you applied for 10 lots and the subscription was 5 times, you might get 2 lots. However, in heavily oversubscribed retail portions, a lottery system is often employed to ensure fair distribution among applicants.
• Non-Institutional Investors (NII) and Qualified Institutional Buyers (QIBs): These categories often see much higher subscription rates (42.36 times for NII and 182.65 times for QIBs in Anthem Biosciences). Allotment in these segments is typically proportionate to the demand.

2. Application Size:

For retail investors, applying for a single lot often has the same probability of allotment as applying for multiple lots, especially when a lottery system is in place due to oversubscription. However, applying for the maximum retail application size can sometimes slightly increase the chances in certain allotment methodologies.

3. Investor Category:

Different investor categories (Retail, NII, QIB) have reserved portions of the IPO. The demand within each category directly impacts the allotment chances for applicants in that category. For instance, QIBs often receive a larger allocation due to their significant investment capacity.

4. Technical Rejections:

Applications can be rejected due to technical errors, such as incorrect PAN details, multiple applications from the same PAN, or incorrect Demat account information. Ensuring accuracy in your application is paramount to avoid such rejections.

5. Registrar’s Allotment Methodology:

Each IPO registrar (in this case, kfintech Technologies) follows a specific allotment methodology approved by SEBI. While the broad principles are consistent, minor variations in their algorithms can affect the final allotment. These methodologies aim to ensure fairness and transparency in the distribution of shares.

Expert View: Financial analysts often advise retail investors to apply for a single lot in heavily oversubscribed IPOs, as it maximizes the chances of getting at least some shares through the lottery system, rather than applying for multiple lots which might not increase the probability of allotment but ties up more capital. [Source: Livemint, Financial Express]

Anthem Biosciences: A Glimpse into the Company

Anthem Biosciences Private Limited is a leading contract research and manufacturing services (CRAMS) company based in India. Established with a vision to provide high-quality research and manufacturing solutions to the global pharmaceutical and biotechnology industries, Anthem Biosciences has carved a niche for itself through its integrated services and commitment to innovation.

Core Business and Offerings:

Anthem Biosciences primarily focuses on:

• Contract Research: Providing research and development services, including medicinal chemistry, process research, and analytical development, to support drug discovery and development programs for its clients.
• Contract Manufacturing: Manufacturing active pharmaceutical ingredients (APIs) and intermediates for various therapeutic areas, adhering to stringent quality and regulatory standards.
• Custom Synthesis: Offering specialized synthesis services for complex molecules and niche chemicals.

The company’s expertise spans across various therapeutic segments, contributing to the development of life-saving drugs and advanced healthcare solutions. Its client base includes global pharmaceutical giants, biotechnology firms, and research institutions.

Industry Landscape and Growth Potential:

The CRAMS sector in India has witnessed robust growth in recent years, driven by factors such as cost-effectiveness, skilled scientific talent, and a strong regulatory framework. Indian CRAMS companies are increasingly becoming preferred partners for global pharmaceutical companies looking to outsource their R&D and manufacturing activities.

Anthem Biosciences is well-positioned to capitalize on this growth trajectory. Its state-of-the-art facilities, experienced scientific team, and strong client relationships provide a competitive edge. The IPO proceeds are likely to be utilized for expansion plans, enhancing research capabilities, and strengthening its market presence, further solidifying its position in the CRAMS industry.

Market Insights: The global pharmaceutical contract manufacturing market size was valued at USD 100.3 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 7.8% from 2024 to 2030. [Source: Grand View Research, Pharmaceutical Contract Manufacturing Market Size, Share & Trends Analysis Report, 2024-2030]

Conclusion: Navigating the IPO Landscape with Knowledge and Principle

The Anthem Biosciences IPO has undoubtedly been a significant event in the Indian primary market, attracting considerable investor interest. For those who participated, understanding the Anthem Biosciences IPO allotment status is the immediate next step, and this guide has provided the necessary tools and links to facilitate that process. Whether you receive an allotment or not, the experience offers valuable lessons in market dynamics and investment strategy.

Beyond the mechanics of checking allotment and navigating post-listing scenarios, this article has also addressed a fundamental concern for many Muslim investors: the Halal investment aspect of IPOs. It is imperative that financial pursuits align with Islamic values and Shariah compliance. By adhering to principles that prohibit interest, involvement in illicit industries, and excessive speculation, investors can ensure their wealth generation is ethically sound. The pharmaceutical sector, while generally permissible, requires careful scrutiny to ensure the company’s operations and financial structure meet stringent Shariah screening criteria.

As the Anthem Biosciences IPO allotment unfolds, remember that informed decision-making, coupled with adherence to ethical and religious principles, forms the bedrock of sustainable and blessed wealth. The market will always present new opportunities, but the wisdom lies in discerning those that are not only financially promising but also morally upright. May your investments be guided by knowledge and integrity.

Frequently Asked Questions (FAQs)

Q1: When will the Anthem Biosciences IPO allotment status be finalized?

A1: The Anthem Biosciences IPO allotment status is expected to be finalized on July 17, 2025. You can check the status on the BSE website, NSE website, or the official registrar (kfintech) website.

Q2: How can I check my Anthem Biosciences IPO allotment status?

A2: You can check your allotment status on the BSE website (bseindia.com/investors/appli_check.aspx), the kfintech website (kosmic.kfintech.com/ipostatus/), or the NSE website (nseindia.com/invest/check-trades-bids-verify-ipo-bids) by entering your Application Number, PAN, or Demat Account Number.

Q3: What is the official registrar for Anthem Biosciences IPO?

A3: kfintech is the official registrar for the Anthem Biosciences IPO.

Q4: What is the listing date for Anthem Biosciences IPO?

A4: The shares of Anthem Biosciences are expected to be listed on BSE and NSE on July 21, 2025.

Q5: What is Grey Market Premium (GMP) and should I rely on it?

A5: GMP is an unofficial indicator of the expected listing price of an IPO. While it reflects market sentiment, it is unregulated and speculative. It should not be the sole basis for your investment decisions. From an Islamic perspective, direct participation in grey market trading for speculative gains may raise Shariah concerns.

Q6: Is investing in Anthem Biosciences IPO Halal?

A6: Investing in an IPO can be Halal if the company’s core business activities are Shariah-compliant (e.g., not involved in alcohol, gambling, or conventional banking) and its financial structure meets specific quantitative criteria (e.g., low debt, minimal non-compliant revenue). A thorough review of Anthem Biosciences’ business model and financials against Shariah screening standards is essential. Consulting a qualified Islamic finance scholar is recommended.

Q7: What should I do if I don’t receive an allotment?

A7: If you don’t receive an allotment, your application money will be refunded starting July 18, 2025. You can then explore other investment opportunities in the market or consider purchasing Anthem Biosciences shares from the secondary market after listing.

Q8: What is the price band for Anthem Biosciences IPO?

A8: The price band for the Anthem Biosciences IPO was fixed at ₹570 per share.

Q9: What was the subscription level for Anthem Biosciences IPO?

A9: The Anthem Biosciences IPO was subscribed 63.86 times overall. The retail portion was subscribed 5.64 times, NII 42.36 times, and QIBs 182.65 times.